Literature DB >> 8285642

Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin.

P H McWhinney1, S Patel, R A Whiley, J M Hardie, S H Gillespie, C C Kibbler.   

Abstract

All 47 sequential blood culture isolates of viridans group streptococci obtained from febrile neutropenic patients receiving quinolone prophylaxis were susceptible to vancomycin, teicoplanin, and imipenem. Resistance to benzylpenicillin (MIC for 50% of isolates [MIC50], 0.125 microgram/ml) and ceftazidime (MIC50, 4 micrograms/ml) was common. Most isolates were susceptible to amoxicillin, co-amoxiclav (amoxicillin-clavulanic acid at a 2:1 ratio by weight), azlocillin, clarithromycin, and erythromycin, with azithromycin showing comparable activity. The MIC90 of sparfloxacin was 1 microgram/ml; those for ciprofloxacin and ofloxacin were > 16 and 16 micrograms/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8285642      PMCID： PMC192417          DOI： 10.1128/AAC.37.11.2493

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  ESGAB breakpoint determination: clarithromycin.

Authors:  I Phillips; J Acar; F Baquero; T Bergan; A Forsgren; B Wiedemann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

2.  Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients.

Authors:  M Venditti; P Baiocchi; C Santini; C Brandimarte; P Serra; G Gentile; C Girmenia; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit.

Authors:  B A Oppenheim; J W Hartley; W Lee; J P Burnie
Journal:  BMJ       Date:  1989-07-29

4.  Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside.

Authors:  S V Sotiropoulos; M A Jackson; G M Woods; R A Hicks; J Cullen; A I Freeman
Journal:  Pediatr Infect Dis J       Date:  1989-11       Impact factor: 2.129

5.  Adult respiratory distress syndrome in neutropenic leukemia patients.

Authors:  J F Vansteenkiste; M A Boogaerts
Journal:  Blut       Date:  1989-06

6.  Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia.

Authors:  J Cohen; J P Donnelly; A M Worsley; D Catovsky; J M Goldman; D A Galton
Journal:  Lancet       Date:  1983 Dec 24-31       Impact factor: 79.321

7.  A scheme for the identification of viridans streptococci.

Authors:  D Beighton; J M Hardie; R A Whiley
Journal:  J Med Microbiol       Date:  1991-12       Impact factor: 2.472

8.  Resistance in oral streptococci after repeated three-dose erythromycin prophylaxis.

Authors:  G A Harrison; W P Stross; M P Rubin; R M Davies; D C Speller
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

9.  Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy.

Authors:  D Valteau; O Hartmann; L Brugieres; G Vassal; E Benhamou; A Andremont; C Kalifa; J Lemerle
Journal:  Bone Marrow Transplant       Date:  1991-06       Impact factor: 5.483

10.  Prevention of bacteremia caused by alpha-hemolytic streptococci by roxithromycin (RU-28 965) in granulocytopenic patients receiving ciprofloxacin.

Authors:  M Rozenberg-Arska; A Dekker; L Verdonck; J Verhoef
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553
View more
  13 in total

1.  Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Authors:  Andrea S Gershon; Joyce C S de Azavedo; Allison McGeer; Krystyna I Ostrowska; Deirdre Church; Daryl J Hoban; Godfrey K M Harding; Karl Weiss; Lewis Abbott; Fiona Smaill; Marie Gourdeau; Gilles Murray; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis.

Authors:  M S Rouse; J M Steckelberg; C M Brandt; R Patel; J M Miro; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antimicrobials.

Authors:  R R Reinert; C von Eiff; M Kresken; J Brauers; D Hafner; A Al-Lahham; H Schorn; R Lütticken; G Peters
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

4.  Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.

Authors:  George Athanassopoulos; Angelos Pefanis; Vissaria Sakka; Dimitrios Iliopoulos; Despina Perrea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  E test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci.

Authors:  S J Rosser; M J Alfa; S Hoban; J Kennedy; G K Harding
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

6.  In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  F Alcaide; J Carratala; J Liñares; F Gudiol; R Martin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.

Authors:  D E Low; J de Azavedo; R Davidson
Journal:  Can J Infect Dis       Date:  1999-03

Review 8.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

9.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

Authors:  G V Doern; M J Ferraro; A B Brueggemann; K L Ruoff
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.